Transparency Market Research
Legionella Testing Market Size & Share to Surpass USD 742.5 million by 2034, Rising a CAGR 7.8%: Analysis by Transparency Market Research, Inc.
September 20, 2024 08:27 ET | Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Legionella testing industry (레지오넬라균 테스트 산업) revenues reached US$323.2 million in 2023. A...
TIP_link_300x300.jpg
Helicobacter Pylori Non-invasive Testing Market Revenue to Cross $800.04Mn, Globally, by 2028 to Growing at 4.4% CAGR – Study by The Insight Partners
August 24, 2022 06:00 ET | The Insight Partners
New York, Aug. 24, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market Forecast to 2028 – COVID-19 Impact...
MicrosoftTeams-image (5).png
Value of Bioanalytical Testing Services Market Estimated at US$ 8.95 Bn by 2031, TMR Report
July 08, 2022 08:30 ET | Transparency Market Research
Wilmington, Delaware, United States, July 08, 2022 (GLOBE NEWSWIRE) -- Transparency Market Research Inc.: TMR study for bioanalytical testing services market statistics, estimates a CAGR of 15.7%...
Diazyme
Diazyme Laboratories, Inc. Receives Second FDA EUA for COVID-19 Antibody Test
August 17, 2020 20:09 ET | General Atomics
SAN DIEGO, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Diazyme announces receiving FDA Emergency Use Authorization (EUA) letter for the Diazyme DZ-Lite SARS-CoV-2 IgM CLIA test. The Diazyme IgM test runs on...
blank.JPG
Diazyme Laboratories, Inc. Receives FDA EUA for COVID-19 Antibody Test
July 08, 2020 20:32 ET | General Atomics
SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Diazyme announces receiving FDA Emergency Use Authorization (EUA) letter for the Diazyme DZ-Lite SARS-CoV-2 IgG CLIA test. The Diazyme IgG test is run on...
GA_Diazyme_white_blue_background
Diazyme Announces Continued Availability of COVID-19 Laboratory Run Antibody Tests
May 22, 2020 18:23 ET | General Atomics
SAN DIEGO, Calif., May 22, 2020 (GLOBE NEWSWIRE) -- Diazyme is making a statement to clear any confusion due to FDA’s May 21 press release regarding delisted tests from the FDA FAQ website. Diazyme...